Conclusion: These results support BAT as a putative metformin target.
| INTRODUCTION
Metformin has been used in the treatment of type 2 diabetes for more than half a century and is currently the recommended first-line oral antidiabetic drug worldwide. Metformin treatment improves glycaemic control and reduces cardiovascular mortality without weight gain or risk of hypoglycaemia 1, 2 ; however, despite its common use, the mechanisms of action of metformin remain to be fully established. In people with type 2 diabetes, metformin treatment can reduce hepatic glucose production, [3] [4] [5] but this finding has not been consistently observed, 6, 7 and in healthy people without diabetes, metformin treatment increases hepatic glucose production. 8, 9 Investigations of the metformin-mediated effects on glucose disposal are also inconclusive, with some results
showing a positive effect, 6, 10 while others show no increase in glucose disposal. 11, 12 This has led to speculation about whether the effect of metformin involves target organs besides liver and skeletal muscle. This notion is supported by evidence of direct effects of metformin on gut hormones 13, 14 and the microbiome. 15 Metformin targets intracellular effectors, leading to suppression of mitochondrial function. [16] [17] [18] Because the drug is hydrophilic, it relies on carrier proteins for cellular uptake. These proteins involve members of the organic cation transporter (OCT) family, plasma membrane monoamine transporter (PMAT) and multidrug and toxin extrusion protein 1 (MATE1). 19 PMAT is found on the luminal side of enterocytes in the intestines, and may be the main transporter responsible for metformin uptake from the gastrointestinal tract.
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OCT1 is mainly present in the liver, OCT2 is primarily found in the kidney, 19, 20 whereas OCT3 is ubiquitously expressed to a variable extent throughout the body. 21 MATE1 is found in multiple organs and is thought to be responsible for metformin excretion in, for example, the liver and kidney cells. 19 Metformin is not metabolized in vivo, but is eliminated through OCT2 and MATE1 in the kidneys. 19 Brown adipose tissue (BAT) is a metabolically highly active organ, which has been proposed as a target in the treatment and prevention of type 2 diabetes and obesity. 22 Brown adipocytes are capable of dissipating chemically bound energy as heat through uncoupling of the respiratory chain by the action of uncoupling protein 1 (UCP1), a protein unique to these cells. 23 In mice, metformin treatment is associated with increased VLDL clearance in BAT 24 and increments in proteins involved in mitochondrial biogenesis. These observations could indicate a direct action of metformin on BAT. This is further supported by the detection of metformin in BAT shortly after intravenous administration of the drug, 16 and increases in gene expression of BAT-associated proteins, UCP1 and ELOVL3, in peritoneal visceral fat during metformin treatment 25 ; however, whether metformin mediates this effect through direct action on the tissue is still to be investigated.
We have recently shown how [ 11 C]-metformin positron-emission tomography (PET) is a novel and robust method of studying the pharmacokinetic properties of metformin in both animals and humans. 20, 26 To test the hypothesis that metformin directly targets BAT, we investigated the biodistribution of metformin in mice in vivo and assessed the potential effects of metformin on human UCP1-positive adipocytes in vitro.
| RESEARCH DESIGN AND METHODS

| Animals
Mice were purchased from Taconic, Silkeborg, Denmark. All animals were group-housed with free access to water and standard chow until the study day. Cages were kept at room temperature (20 C The reconstructing protocol has been published previously. 28 In short, 60-minute dynamic PET scans were reconstructed with increasing duration from 5 seconds to 10 minutes (30 frames in all). Images from the MRI were used to define the size and demarcation of the liver, heart and interscapular area. 
| Human deep neck AT biopsies
Human AT biopsies from the subcutaneous neck AT and deep-neck AT were collected during elective surgery as previously described. 30 None of the study participants had diabetes nor were they administered β-adrenergic antagonists. All biopsies were collected in a period from late January until the middle of March 2015. Each participant had one subcutaneous AT biopsy taken and 1 to 3 deep-neck AT biopsies. This resulted in a total of 12 subcutaneous AT biopsies and 24 deep-neck AT biopsies that were instantly frozen in liquid nitrogen.
All study participants gave informed written consent. The study was approved by the Central Denmark Region ethics committee and was performed in accordance with the Declaration of Helsinki.
| RNA isolation and quantitative real-time PCR
Total RNA from all dissected tissues was isolated with TRIzol reagent (Ambion, Life Technologies, Carlsbad, California). The cDNA was synthesized using random hexamer primers by the Verso cDNA Kit 
| In vitro oxygen consumption and extracellular acidification measurements
Immortalized brown adipocytes of human origin (TERT-hBA), passage 10-12, were cultured as previously described. 31 On day 9 of differentiation, cells were replated into gelatin-covered 96-well XF Cell Culture Microplates (20 000 cells/well). Cells were kept in growth medium (Advanced DMEM/F12) supplemented with 2% FBS, penicillin (62.5 μg/mL), streptomycin (100 μg/mL), L-glutamine (2 mM) and T3 (1 nM) for 2 days. Immortalized white adipocytes of human origin (TERT-hWA), 31 passage 12-13, and hMADS cells 32 were cultured as described. 31 On day 9 of differentiation, cells were replated as described above. Cells were kept in growth medium without T3. On day 12, cells were treated with rosiglitazone (1 μM) to induce browning. 31 Analyses were conducted on day 15. Twenty-four hours before the analyses, the medium was changed to growth medium, At all time points, OCR was established as a mean of the measurements from 10 to 15 wells after discarding technical outliers.
For gene expression analysis, three separate plates of TERT-hBA cells were differentiated and snap frozen in liquid nitrogen on day 11.
| Statistical analyses
Data distribution was assessed by qq-plots. When uneven distribution was identified, data were logarithmically transformed to obtain a normal distribution. The murine data were compared using the Student's t test or ANOVA with Bonferroni's correction for multiple comparisons (post hoc analysis) and expressed as mean AE SE. When assessing human biopsy material, intrapersonal dependence was taken into account by clustering SE on the level of the individual. 30 Cell intervention analyses within the same passage were compared using a paired t test. A P value of <0.05 was considered statistically significant.
Statistical analyses were performed using GraphPad PRISM 5.01 for windows and STATA 13.1 for windows.
3 | RESULTS
| Metformin is distributed to BAT in mice in vivo
Intravenous administration of [ 
| OCT3 gene expression is enriched in BAT from mice and humans
To test if the gene expression profile of metformin transporter proteins in BAT is similar in mice and humans, AT was collected from both species. In mice, AT from the interscapular and inguinal depots was dissected and analysed for Ucp1 gene expression. As expected,
Ucp1 expression was high in the interscapular depot and barely detectable in the subcutaneous inguinal adipose depot ( Figure 3A) , thereby demonstrating the classic location of BAT in mice.
In humans, deep-neck AT biopsies from study participants undergoing elective neck surgery were assessed. The participant characteristics are shown in Table 1 . Expression of UCP1 in human deep-neck
AT showed a large degree of heterogeneity, ranging from undetectable UCP1 mRNA to levels comparable to those found in murine BAT ( Figure 3A) . Gene expression profiling of metformin transporters [ Figure 4C ]), but did not affect ECAR ( Figure 4D ).
Next, we studied cellular respiration after prolonged exposure (24 hours) to 0.1 and 0.5 mM metformin in two additional human thermogenic cell models (TERT-hWA and hMADS). Both cell-lines were "browned" by treatment with rosiglitazone from days 12 to 15, as described previously. 31 Oxygen consumption in the hMADS cell model was reduced by 9% during incubation with 0.1 mM metformin (P < .01) and by 42% during incubation with 0.5 mM metformin (P = .03; Figure 5A ). Similar to short-term exposure, the OCR was also reduced by metformin during chemical uncoupling ( Figure 5A ). As shown in Figure 5B , metformin had similar effects in TERT-hWA cells.
During prolonged exposure to 0.5 mM metformin, the ECAR increased by 39% in the hMADS cell line (P < 0.01) and 33% in the TERT-hWA cell model ( Figure 5C,D) , while no effect on ECAR by 0.1 mM metformin was observed.
| DISCUSSION
The present study shows that metformin targets BAT in vivo in rodents through OCT-mediated uptake. Previous studies have shown abundant uptake of metformin in the liver, kidneys, salivary glands and the intestinal mucosa, 14 while small amounts of metformin may be transported into white AT and muscle. 16, 33 The metformin exposure in BAT demonstrated in this study was similar in magnitude to exposure in the liver, a well-established metformin target organ. 19 Metformin may therefore directly target substrate metabolism in BAT.
The pharmacokinetic profile of metformin in BAT does not resemble hepatic distribution. Similarly to the liver, the interscapular BAT is highly vascularized, 34 suggesting that the difference in metformin distribution is not solely explained by differences in vascularization.
Instead, the difference in the pharmacokinetic profile can be a consequence of a difference in transporter protein profiles between the two tissues. The pronounced reduction in uptake of metformin in BAT during co-administration with cimetidine shows that metformin uptake in BAT indeed depends on normal function of transporter proteins. The half-maximal inhibitory concentrations (IC 50 ) of cimetidine on OCT1, OCT2 and OCT3 are similar, 35 and administration of cimetidine does therefore not provide evidence for which OCT-isoform is involved. The minute effect of combined ablation of OCT1 and OCT2
and the results from the gene expression studies suggests that OCT3
is probably facilitating uptake of metformin into BAT. The capacity of OCT3 to transport metformin in selected tissues is evident in OCT3 −/− mice where accumulation of metformin in salivary glands is abolished. 36 OCT3 is widely expressed in multiple tissues 21 and, interestingly, OCT3 knockout is associated with attenuated response to metformin treatment. 21 This shows that at least some of the pharmacodynamic actions of metformin are mediated through this transporter; however, the present study does not provide direct evidence that OCT3 is the mediator of metformin uptake in BAT, and the involvement of other transporter proteins cannot be excluded. (n = 4) and wild-type mice (n = 7). C, Distribution in pyrimethaminetreated mice (n = 4) and control mice (n = 3). Data are mean AE SEM values. Error bars that are not visible are contained within the symbols. *P < .05
We have previously determined whole-body metformin distribution in four healthy human subjects in vivo. 20 In these subjects, we detected marginal uptake of metformin in the neck area, which was predominantly confined to the parotid glands, a well-known target organ of metformin 36 ; however, BAT presence was not determined in the study subjects. 37 Unlike rodents, brown adipocytes in humans are typically scattered within large depots of white AT. There is substantial interpersonal variation in BAT amount, 37 but BAT is often enriched in the deep-neck AT. 37 Direct investigations of [ 11 C]-metformin uptake in human BAT, therefore, require determination of BAT location in a separate scan, for example, using FDG-PET during cold exposure. 37 Although not providing direct evidence of metformin uptake in human BAT, the gene expression profile of UCP1-containing adipocytes from deep-neck AT in humans suggests that metformin uptake in human BAT is likely. OCT3 is encoded by the SLC22A3 gene, and it is the most abundantly expressed metformin transporter in human deep-neck AT, and UCP1 and SLC22A3 gene expression levels closely correlate in human deep-neck AT. 30 Several lines of evidence imply that metformin inhibits complex-1 in the inner mitochondrial membrane, 17, 18 and thereby reduces substrate oxidation. 18 This is consistent with the reduced OCR in TERT-hBA cells observed in the present study, and with observations in mice where treatment with metformin increases both expression and activation of AMPK in BAT. 24 Metformin action on BAT may not necessarily be confined to inhibition of mitochondrial function, but may also interact with OCT activity. OCT3 functions as a contributing regulator of extracellular catecholamine levels by facilitating local removal of endogenous amines.
Metformin is a competitive substrate of OCT transport 38 and may thereby increase β-adrenergic receptor stimulation in BAT. In rodents, norepinephrine stimulation of brown preadipocytes and mature adipocytes will lead to recruitment in BAT. 39 This mechanism may translate to humans because increases in BAT mass and activity have been observed in patients with pheochromocytoma and paraganglioma. 33, 40 Interestingly, metformin treatment of immortalized murine brown OCT1  OCT2  OCT3  MATE1  PMAT  OCT1  OCT2  OCT3  MATE1  PMAT  OCT1  OCT2  OCT3  MATE1  PMAT  OCT1  OCT2  OCT3  MATE1  PMAT  OCT1  OCT2  OCT3  MATE1  PMAT  OCT1  OCT2  OCT3  MATE1 Gene expression analyses were performed on human adipose tissue biopsies collected from the neck area of patients admitted for elective neck surgery at Aarhus University Hospital.
adipocytes acutely increases p44/p42 mitogen-activated protein kinase (MAPK) activation and reduces leptin secretion. 41 In addition, metformin treatment may rescue obesity-induced suppression of brown adipogenesis and thermogenesis. 42 Also, 2 weeks of daily metformin administration to rats increases Ucp1 expression in the postprandial state 43 and 14 weeks of daily metformin administration increases expression of genes associated with BAT in mice. 25 Hence, metformin action on BAT may assert both acute and more prolonged effects on BAT function.
Metformin levels in plasma vary greatly among people with diabetes under controlled conditions. 44 Therapeutic levels have been suggested to be between 0.7 and 7 μM, 45 but consensus has not been established. 46 During clinical use, plasma metformin levels between 0 and 113 mg/L (868 μM) have been measured in random blood samples from people with diabetes. 47 The decrease in cellular respiration in TERT-hBA cells during short-term metformin exposure was observed using high to supra-pharmacological metformin concentrations. As demonstrated in our gene expression profiles, the gene expression levels of SLC22A3 in TERT-hBA cells were more than 10-fold lower compared with AT from the human deep neck; therefore, to facilitate cellular uptake during in vitro conditions high concentration of metformin was necessary. The increased ratio of SLC47A1 (MATE1) to SLC22A3 (OCT3) expression may also be a contributing factor to a low uptake of metformin in TERT-hBA cells as MATE1 facilitates excretion of metformin from the cell. 48 Concentrations of ≥1 mM are often used for in vitro studies, 18, 49 but to study the effects of metformin in human brown adipocytes under conditions better resembling the in vivo situation, we chose a lower concentration and a longer exposure time. Furthermore, to test if the effects of metformin were confined to only TERT-hBA cells, we used two additional cell models with a different metformin transporter transcription profile. Importantly, in one of these (hMADS) transcription of the efflux-transporter, MATE1, is low. 50 In both hMADS and TERT-hWA, metformin decreased oxygen consumption in 0.1 mM concentrations. In addition, prolonged exposure to metformin increased the ECAR, which may be attributable to increased glycolytic rate or increased CO 2 production. 51 These in vitro results demonstrate the direct cellular effects of metformin in cells expressing UCP1, but the direct effects of metformin in BAT in humans remain to be established.
In conclusion, our data show that OCTs facilitate avid uptake of metformin in mouse BAT in vivo. This finding may be translated to humans as gene expression profiles of metformin transporter proteins in BAT are conserved between species. In immortalized brown adipocytes of human origin, metformin decreases cellular respiration, which supports a direct pharmacological action of the drug in BAT. Collectively, the data suggest that BAT is a potential target organ of metformin action. Relative OCR (%) FIGURE 5 Human browned adipocytes exposed to prolonged metformin treatment. The human cell lines hMADS (n = 3) TERT-hWA (n = 2) were converted to their beige phenotype and incubated with metformin 0.1 and 0.5 mM for 24 hours. A and B, oxygen consumption rate (OCR) and C and D, extracellular acidification rate (ECAR) under basal conditions and after chemical uncoupling by FCCP. As basal OCR and ECAR differed between the cell models, OCR is depicted as pct of control cells. *P < .05. **P < .01
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